• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·BALAXI.NS
Share

Balaxi Pharmaceuticals Limited Stocks

₹ 24.39Last Updated 27.07.2026

Issuer Rating

3/7
Performance

Average

Risk

Considerable

Recommendation

Sell

Market Cap

₹ 2.82M

₹ 24.39
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Balaxi Pharmaceuticals Limited, through its entity Balaxi Ventures Ltd., primarily operates as an international wholesale distributor specializing in pharmaceuticals, various food items, and hardware supplies. The company's corporate base is situated in Hyderabad, Telangana. Its extensive product range features pharmaceutical formulations, a variety of food products, and construction-related hardware. Notably, both its pharmaceutical and builders' hardware offerings are manufactured under contract at different plants located across India. Within its food segment, the firm markets a selection of food and biscuit products under the recognizable brand name YAP. Balaxi Global DMCC is among the key subsidiaries within the company's structure.

Company Valuation

Undervalued
6/7

Based on key historical and expected multiples, the stock is undervalued relative to its peers. In particular, the stock is overpriced on P/E, 'cheap' on EV/EBITDA, under

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

29.07.2026 23:01

The Fed has kept interest rates unchanged for the fifth consecutive time. What's next?

29.07.2026 22:23

"It's a Matter of Lost Trust": Chipmakers Lost More Than $1 Trillion in Market Capitalization in Two Days

29.07.2026 22:06

Novo Will Sue Investors Over the Results of a Study on a Weight-Loss Drug

29.07.2026 21:47

Insiders in the AI boom were among the biggest sellers on the eve of the chipmakers' crash

29.07.2026 20:35

Noble is first on Wall St. to cover Beasley Broadcast Group, seeing almost 50% upside

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026